Published in PLoS One on July 18, 2012
Fixed Combination for Lipid and Blood Pressure Control (FILIP) | NCT03047538
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation (2016) 1.40
The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One (2012) 1.00
Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Evid Based Complement Alternat Med (2014) 0.97
Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT trial). PLoS One (2014) 0.85
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. Eur J Epidemiol (2016) 0.84
Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. Eur J Epidemiol (2014) 0.83
Prehypertension: Underlying pathology and therapeutic options. World J Cardiol (2014) 0.80
Starting the polypill: the use of a single age cut-off in males and females. J Med Screen (2016) 0.78
Assessing population aging and disability in sub-Saharan Africa: lessons from Malawi? PLoS Med (2013) 0.78
Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis. J Cardiovasc Dis Res (2013) 0.77
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res (2016) 0.76
Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill. Curr Hypertens Rep (2016) 0.76
Prevention: Polypills reduce CVD risk factors. Nat Rev Cardiol (2012) 0.75
Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assess (2013) 0.75
Drugs: Blood battles. Nature (2013) 0.75
Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One (2017) 0.75
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 11.21
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 8.55
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract (2010) 2.57
Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol (1996) 2.37
Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One (2011) 1.56
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials (2011) 1.27
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension (2002) 1.23
The Indian Polycap Study (TIPS). Lancet (2009) 1.03
The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open (2011) 0.90
Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J Eval Clin Pract (2011) 0.87
Aspirin in the prevention of cancer. Lancet (2011) 0.85
Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med (2013) 11.03
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ (2002) 7.14
First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med (2005) 4.89
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med (2009) 3.85
Antenatal thyroid screening and childhood cognitive function. N Engl J Med (2012) 3.75
Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ (2007) 3.64
The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med (2002) 3.32
Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med (2010) 2.94
Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation (2005) 2.87
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ (2010) 2.77
Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenat Diagn (2006) 2.06
Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ (2006) 1.93
Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ (2005) 1.92
Breast screening saves lives. BMJ (2009) 1.58
Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One (2011) 1.56
Assessing risk factors as potential screening tests: a simple assessment tool. Arch Intern Med (2010) 1.55
Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet (2012) 1.51
Teleoanalysis: combining data from different types of study. BMJ (2003) 1.48
Vitamin B-12 and folate deficiency in elderly persons. Am J Clin Nutr (2004) 1.43
Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation (2002) 1.35
The efficacy of combining several risk factors as a screening test. J Med Screen (2005) 1.34
The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn (2010) 1.30
Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis (2003) 1.22
Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol (2002) 1.11
Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One (2011) 1.09
Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn (2006) 1.03
De novo apparently balanced translocations in man are predominantly paternal in origin and associated with a significant increase in paternal age. J Med Genet (2009) 1.01
The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. Eur J Cardiovasc Prev Rehabil (2004) 0.97
The polypill concept. Heart (2010) 0.97
Mortality from hypertrophic cardiomyopathy in England and Wales: clinical and screening implications. Int J Cardiol (2004) 0.96
Discounting the value of life. J Med Screen (2011) 0.95
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open (2013) 0.90
Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004-2011. Am J Med Genet A (2013) 0.89
De novo deletions and duplications detected by array CGH: a study of parental origin in relation to mechanisms of formation and size of imbalance. Eur J Hum Genet (2011) 0.87
Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J Eval Clin Pract (2011) 0.87
Body weight reduction to avoid the excess risk of type 2 diabetes. Br J Gen Pract (2012) 0.86
Trends in maternal age distribution and the live birth prevalence of Down's syndrome in England and Wales: 1938-2010. Eur J Hum Genet (2013) 0.86
Risk estimation versus screening performance: a comparison of six risk algorithms for cardiovascular disease. J Med Screen (2013) 0.86
Community Corner: Opening the Pandora's box of prenatal genetic testing. Nat Med (2011) 0.84
Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenat Diagn (2008) 0.84
The Polypill in the prevention of cardiovascular disease. Prev Med (2010) 0.83
Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. Eur J Epidemiol (2014) 0.83
Cytological and epidemiological findings in trisomies 13, 18, and 21: England and Wales 2004-2009. Am J Med Genet A (2012) 0.82
Recurrence risks for trisomies 13, 18, and 21. Am J Med Genet A (2009) 0.82
Haemoglobin level at birth is associated with short term outcomes and mortality in preterm infants. BMC Med (2015) 0.81
First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency. J Med Screen (2008) 0.81
The population prevalence of Down's syndrome in England and Wales in 2011. Eur J Hum Genet (2013) 0.80
Folic acid fortification in the prevention of neural tube defects. Am J Clin Nutr (2004) 0.80
Child-parent screening for familial hypercholesterolemia. J Pediatr (2011) 0.79
The polypill in the primary prevention of cardiovascular disease. Fundam Clin Pharmacol (2009) 0.79
Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn (2004) 0.79
Three stage contingent screening for Down syndrome. Prenat Diagn (2006) 0.79
An audit of the detection of trisomy 18 in prenatal screening for Down syndrome using the Combined test. Prenat Diagn (2011) 0.79
Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers. J Med Screen (2012) 0.78
Changes in maternal age in England and Wales--implications for Down syndrome. Downs Syndr Res Pract (2006) 0.78
Down syndrome and paternal age, a new analysis of case-control data collected in the 1960s. Am J Med Genet A (2009) 0.78
Preventive angioplasty in myocardial infarction. N Engl J Med (2014) 0.77
Birth prevalence and survival of exomphalos in england and wales: 2005 to 2011. Birth Defects Res A Clin Mol Teratol (2014) 0.77
Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn (2006) 0.77
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. J Med Screen (2012) 0.77
The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A (2011) 0.77
Erratum to: Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. Eur J Epidemiol (2015) 0.77
Personalized medicine: hope or hype. Eur Heart J (2012) 0.77
The polypill concept. Postgrad Med J (2010) 0.77
Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn (2002) 0.77
Apolipoprotiens and prediction of fatal myocardial infarction. Lancet (2002) 0.76
Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. J Med Screen (2013) 0.76
Commentary: a brief history of folic acid in the prevention of neural tube defects. Int J Epidemiol (2011) 0.76
A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. Clin Ther (2008) 0.76
Efficacy and safety of cholesterol-lowering treatment. Lancet (2006) 0.75
Familial hypercholesterolaemia: screening needs a fresh approach. BMJ (2007) 0.75
Rates of Down syndrome at the upper extreme of maternal age: considerations and recommendations in analysis. Prenat Diagn (2006) 0.75
Contingent screening for Down syndrome. Prenat Diagn (2008) 0.75
Folate and risk of cardiovascular disease. Study results were misinterpreted. BMJ (2003) 0.75
First-trimester screening for Down's syndrome. N Engl J Med (2004) 0.75
Cost-effectiveness of diagnosis of high blood pressure in primary care. Lancet (2012) 0.75
Truncation limits for CT marker ratios in prenatal screening for Down syndrome. Prenat Diagn (2007) 0.75
Obesity and public health law. N Engl J Med (2006) 0.75
Which gestational age estimate to use in AFP screening for spina bifida? Prenat Diagn (2005) 0.75
Paternal age and birth defects: how strong is the association. Hum Reprod (2007) 0.75
Recurrent false-positives in AFP screening for open neural tube defects. Prenat Diagn (2004) 0.75
Antenatal screening policies for Down's syndrome. Audit of Down's syndrome screening is not valid. BMJ (2002) 0.75
Prevention of Late Onset Sepsis and Central-line Associated Blood Stream Infection in Preterm Infants. Pediatr Infect Dis J (2016) 0.75
Meta-analysis audit trail. Lancet (2008) 0.75
Genetic testing. J Med Screen (2011) 0.75
When screening is still not enough. J Med Screen (2006) 0.75
The Canadian recommendations on screening for type 2 diabetes. J Med Screen (2012) 0.75
Some clarity in the management of DCIS in breast cancer screening. J Med Screen (2011) 0.75